Filing Flows › Silence Therapeutics (SLN) › Q4 2025
Silence Therapeutics (SLN) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 5, 2026
Silence Therapeutics (SLN) reported revenue of $34K for the fourth quarter 2025 (Q4 2025), -100% from a year earlier and -79% from the quarter before.
Silence Therapeutics, Q4 2025: revenue $34K (-100% year over year), net loss $11.8M, operating cash flow −$17.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $34K | -79% | -100% |
| Operating profit | −$12.5M | — | — |
| Net earnings | −$11.8M | — | -196% |
| Operating cash flow | −$17.3M | — | — |
What changed
Revenue was $34K in Q4 2025, down 100% year over year and down 79% from the previous quarter.
Gross margin was 64.7%, down 27.2 points from Q4 2024. Operating costs exceeded revenue by $12.5M, an operating margin of -36650.0%. Operating expenses fell 55% while revenue fell 100%. The quarter ended with a net loss of $11.8M, narrower than the previous quarter's $21.0M loss.
Operating cash flow was −$17.3M. Non-cash charges added back $77K of depreciation. Working capital and other items used $5.6M.
Questions
What was Silence Therapeutics' revenue in the fourth quarter 2025?
Silence Therapeutics (SLN) reported revenue of $34K for the fourth quarter 2025 (Q4 2025), -100% from a year earlier and -79% from the quarter before.